aflibercept

Key facts

INN

aflibercept

Brand

EYLEA

Route

INJECTION

Formulation

INJECTABLE

Originator

REGENERON PHARMACEUTICALS, INC.

Related patents

patent

US 11667702

Stable aqueous formulations of aflibercept

Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 11535663

Methods for producing aflibercept in chemically defined media having reduced afl

Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 11472861

Methods for producing aflibercept in chemically defined media having reduced afl

Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 11426446

Stable aqueous formulations of aflibercept

Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 11104715

Methods for producing aflibercept in chemically defined media having reduced afl

Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 11071780

Methods and formulations for treating vascular eye diseases using aflibercept an

Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

Frequently asked questions

What is aflibercept?

aflibercept (EYLEA), is a pharmaceutical active ingredient, associated with REGENERON PHARMACEUTICALS, INC., with approved status in the US.

What is the brand name for aflibercept?

EYLEA is a marketed brand name for aflibercept. Check FDA Drugs@FDA for the current US label holder.